11
Total investments
5
Early stage
1
Mid stage
1
Late stage
5y
Years active
Portfolio
10 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Jun 2026
Science Corporation is a clinical-stage medical technology company. We work to restore quality of life to those with debilitating conditions for which there are no treatment options, creating devices aimed at restoring vision, cognition, and mobility to patients who have lost it. To support progress across our industry, we provide state-of-the-art components and vertically integrated infrastructure for others to build on via Science Foundry.
Headquartered in Alameda, California, with offices in Paris, France.
Co-Founding Advisor & Shareholder
Jan 2026
We are building the trust infrastructure that allows enterprises to deploy multilingual AI systems that are not only accurate but also aligned with company rules, internal policies, corporate knowledge, and regulatory requirements, sitting between AI systems and real-world users.
We are a research-driven team building core foundational technology to unlock trustworthy AI via open efficient language models and multilingual agents designed for safety and reliability.
As AI systems become more autonomous and mission-critical, companies face growing risks around compliance, reputational damage, and loss of control, especially in markets where expectations around transparency, explainability, accountability, and oversight are high. Our technology ensures AI behaves in line not only with general safety and compliance policies but also with the unique principles of each organization — by design, not after the fact.
Investor
Nov 2025
Juniper Biosciences is a radiopharmaceutical company focused on developing its pipeline of innovative products
Investor
Oct 2024
Healthcare designed to keep you healthy and out-of-hospital. 💙
Even is a healthcare company based out of Bengaluru that offers comprehensive health covers for individuals and businesses. Evens plans offer more than just the safety of hospitalisation. How, you ask?
With Even, you get
> Free doctor consultations ✅
> Lab and radiology tests ✅
> Unlimited access to specialists (dermat, physio, nutritionists etc) ✅
> Preventive Care for parents ✅
> Optional insurance benefits ✅
> Free access to Even Clinics ✅
> and a lot more ✅
Even is backed by Alpha Wave, Khosla Ventures, Lightrock India and 7 other investors.
Investor
Jun 2024
Were an AI research company that builds reliable, interpretable, and steerable AI systems. Our first product is Claude, an AI assistant for tasks at any scale.
Our research interests span multiple areas including natural language, human feedback, scaling laws, reinforcement learning, code generation, and interpretability.
Series B Investor
May 2024
Understand the Universe. We are a team of AI technologists and business leaders on a mission to build AI systems that can help humanity understand the world better. https://x.ai/careers
Pre-Seed Investor
Nov 2023
Talentware is an innovative platform designed to revolutionize the way companies manage their talent.
Unlike standard HR software, Talentware offers the first employee-centric platform that enables businesses to engage, grow, and retain talent through a skill-based journey.
In todays fast-paced business environment, organizations need to focus on employee development centered around skills rather than just work history or degrees. If you are wondering how to transition from a role-based to a skill-based talent management approach, Talentware is the right tool for you.
Seed Investor
May 2022
Since launching in 2021 newcleo has quickly established itself as innovator in the field of nuclear energy. newcleo is working to design, build, and operate Gen-IV Advanced Modular Reactors (AMRs) that are cooled by liquid lead and fuelled by reprocessed nuclear waste.
Through an innovative combination of existing and proven technologies, and by reviving a nuclear industry model based on the manufacture and multi-recycling of Mixed Oxide fuel, newcleo aims to close the nuclear fuel cycle while safely producing clean, affordable, and practically inexhaustible energy required for low carbon economies.
With a EUR 50m group turnover in 2024, more than EUR 537m of private funding and over 90 partnerships and collaborations across the nuclear industry, the growth of the newcleo group is supported through the targeted acquisition of key companies with strong capabilities in nuclear engineering, manufacturing, and waste management.
Through its workforce of over 950 highly qualified employees across France, the UK, Italy, Switzerland and Slovakia, newcleo is not only developing and delivering the skills and services required for the group’s own ambitious project timelines, but also supporting the development of Small Modular Reactor supply chains in Europe and beyond.
Debt Investor (converted at Series C)
May 2021
D-Orbit is a global market leader in the space logistics and transportation service industries with a track record of space-proven technologies and successful missions. The company has developed proprietary space logistics technology and transportation solutions to accelerate the growth and development of a trillion-dollar space economy through an incremental strategic approach to the space marketplace to deliver successful customer outcomes today while developing advanced products and services for the needs of tomorrow.
D-Orbit was founded in 2011. With a manifest of future missions fully booked by new and returning customers, the company has already successfully flown over 70 payloads. D-Orbit is the first company to address the logistics needs of the space market. Its forward-thinking view has enabled it to consistently create solutions for its customers that save them money and time, like ION Satellite Carrier, a vehicle that can transport satellites in orbit and release them individually into distinct orbital slots, and a proprietary cloud-based mission control software suite designed to control entire satellite constellations.
As it looks to the future, D-Orbit is already developing and testing new technologies to extend the life of satellites in orbit, perform active debris removal, enable interplanetary space logistics, and more. D-Orbit is creating an infrastructure that will broaden humankind’s opportunities to operate in space and expand into the solar system.
Privacy policy https://bit.ly/2EPbIM2
Experience · 15 entries
All (15)
Investments (11)
2026
Investor
Jun 2026
Science Corporation is a clinical-stage medical technology company. We work to restore quality of life to those with debilitating conditions for which there are no treatment options, creating devices aimed at restoring vision, cognition, and mobility to patients who have lost it. To support progress across our industry, we provide state-of-the-art components and vertically integrated infrastructure for others to build on via Science Foundry.
Headquartered in Alameda, California, with offices in Paris, France.
Investor
Feb 2026
SpaceX designs, manufactures and launches the world’s most advanced rockets and spacecraft. The company was founded in 2002 by Elon Musk to revolutionize space transportation, with the ultimate goal of making life multiplanetary.
SpaceX has gained worldwide attention for a series of historic milestones. It is the only private company ever to return a spacecraft from low-Earth orbit, which it first accomplished in December 2010. The company made history again in May 2012 when its Dragon spacecraft attached to the International Space Station, exchanged cargo payloads, and returned safely to Earth — a technically challenging feat previously accomplished only by governments. Since then Dragon has delivered cargo to and from the space station multiple times, providing regular cargo resupply missions for NASA.
For more information, visit www.spacex.com.
Co-Founding Advisor & Shareholder
Jan 2026
We are building the trust infrastructure that allows enterprises to deploy multilingual AI systems that are not only accurate but also aligned with company rules, internal policies, corporate knowledge, and regulatory requirements, sitting between AI systems and real-world users.
We are a research-driven team building core foundational technology to unlock trustworthy AI via open efficient language models and multilingual agents designed for safety and reliability.
As AI systems become more autonomous and mission-critical, companies face growing risks around compliance, reputational damage, and loss of control, especially in markets where expectations around transparency, explainability, accountability, and oversight are high. Our technology ensures AI behaves in line not only with general safety and compliance policies but also with the unique principles of each organization — by design, not after the fact.
2025
Investor
Nov 2025
Juniper Biosciences is a radiopharmaceutical company focused on developing its pipeline of innovative products
Show all 15 entries ↓
Investment activity
2021–2026 · 11 investments
Recent (last 2 years)Earlier
